Skip to main content

Featured

Canada's Rent Slide Is Finally Stalling — What It Means If You Rent or Rent Out

  Published August 13, 2026 For nearly two years, "Canadian rents are falling" has been one of the safest headlines in personal finance. The August 2026 National Rent Report from Rentals.ca and Urbanation, released last week, suggests that streak may finally be running out of road — and the shift matters whether you're the one paying rent or the one collecting it. The Numbers National avg. asking rent (July) $2,037 Year-over-year change -4.0% (22nd straight monthly decline) Month-over-month change +0.2% (4th straight monthly rise) Toronto, month-over-month +1.6% to $2,577 Falling, But Not as Fast Rent is still dropping on a year-over-year basis nationally — that's now been true for 22 straight months. But the pace of the decline has been easing since it bottomed out in March, and July marked the smallest annual drop since February. On a month-to-month basis, rent has now risen for four months running, which typically happens every summer as the market hits its season...
Post a Comment
Read more

article

Labels

A New Dawn in Alzheimer’s Prevention: The AHEAD 3-45 Study


The AHEAD 3-45 study represents a beacon of hope for individuals like Tyson Haller, who, at 60, is determined to understand and possibly prevent the onset of Alzheimer’s—a disease that claimed his father. This groundbreaking clinical trial is testing lecanemab, an FDA-approved drug that has shown promise in slowing Alzheimer’s progression in its early stages. The optimism surrounding this trial is palpable, as it could herald a new era where Alzheimer’s is as manageable as Type 2 diabetes.

  • Family History’s Weight: Haller’s participation is driven by his family’s battle with Alzheimer’s, highlighting the emotional and proactive steps taken by those at risk.
  • Lecanemab’s Potential: The trial’s focus on lecanemab, a drug targeting beta amyloid plaques in the brain, offers a glimpse into a future where early intervention could significantly slow the disease’s impact.
  • Scientific Debate: Despite the excitement, there’s a scientific debate about beta amyloid’s role in Alzheimer’s, underscoring the complexity of finding a definitive treatment.
  • Awaiting Results: With the AHEAD and TRAILBLAZER prevention trials running until 2027 and 2029, patients, doctors, and researchers are in a state of limbo, hopeful yet uncertain of the long-term outcomes.

This study not only represents a potential turning point in Alzheimer’s research but also embodies the personal stories of those fighting to preserve their memories and identities against this relentless disease.

Labels:

Comments

Post a Comment